Details
Stereochemistry | RACEMIC |
Molecular Formula | C10H15NO2 |
Molecular Weight | 181.2316 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCC(O)C1=CC=CC(O)=C1
InChI
InChIKey=SQVIAVUSQAWMKL-UHFFFAOYSA-N
InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3
Molecular Formula | C10H15NO2 |
Molecular Weight | 181.2316 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.sopharma.com/etilefrine.phpCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/26240886
https://en.wikipedia.org/wiki/Etilefrin
Sources: https://www.sopharma.com/etilefrine.php
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/26240886
https://en.wikipedia.org/wiki/Etilefrin
Etilefrine is a cardiac stimulant used as an antihypotensive. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return and blood pressure in man and experimental animals, suggesting stimulation of both α and β adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β1 (cardiac) than for β2 adrenoreceptors. Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure and mean arterial pressure of healthy individuals. Marked falls in pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2,5 mg. These findings indicate that etilefrine has both β1 and α1 adrenergic effects in man. The French Health Products Agency concluded that etilefrine and heptaminol have an unfavourable harm-benefit balance, and also placed restrictions on the use of midodrine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4790080 |
|||
Target ID: CHEMBL213 Sources: http://www.ncbi.nlm.nih.gov/pubmed/4790080 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/12181066 |
Preventing | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. | 1989 Nov |
|
Alfentanil combined with vecuronium or pancuronium: haemodynamic implications. | 1992 Jul |
|
Effect of midodrine on chlorpromazine-induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. | 2000 Dec |
|
Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy. | 2001 |
|
Effects of hypertonic 75 mg/ml (7.5%) saline on extracellular water volume when used for preloading before spinal anaesthesia. | 2001 Jul |
|
Management of sickle cell priapism with etilefrine. | 2001 Jul |
|
[Priapism in the course of generalized atopic dermatitis]. | 2002 Aug-Sep |
|
Hypotension on CAPD: can use of vasoconstrictive drugs be harmful? | 2002 Jan-Feb |
|
[Management of priapism in sickle-cell diseases with alpha-adrenergic agonists]. | 2002 Jul-Sep |
|
Management of thoracic duct injuries after oesophagectomy (Br J Surg 2001: 88: 1442-8). Letter 1. | 2002 Jun |
|
Long-term outcome of patients with asystole induced by head-up tilt test. | 2002 Mar |
|
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma. | 2002 Oct |
|
Etilefrine for the prevention of priapism in adult sickle cell disease. | 2002 Sep |
|
Tilt table test: state of the art. | 2003 Oct 1 |
|
Randomized clinical trials of neurally mediated syncope. | 2003 Sep |
|
Priapism in a patient with unstable hemoglobin: hemoglobin Köln. | 2003 Sep |
|
The importance of interrupting angiotensin converting enzyme inhibitor treatment before spinal anaesthesia--a controlled case report. | 2004 |
|
Etilefrine use in the management of post-operative chyle leaks in thoracic surgery. | 2004 Mar |
|
Apical uptake of choline and cationic drugs in epithelial cell lines derived from human placenta. | 2005 Feb-Mar |
|
[A patient with Shy-Drager syndrome managed under general anesthesia with thoracic epidural anesthesia]. | 2005 Jul |
|
[Management of postoperative chylothorax]. | 2006 Apr |
|
Chylothorax. | 2006 Aug |
|
Investigational agents for sickle cell disease. | 2006 Aug |
|
[Cervical lymphorrea after nodal dissection: role of fasting based on clinical evidence]. | 2006 Feb |
|
Clinical observations surrounding an increased incidence of postanesthetic myopathy in halothane-anesthetized horses. | 2006 Mar |
|
Anaesthesia with remifentanil infusion in diabetic versus non-diabetic patients undergoing vitrectomy. A Holter-controlled study. | 2007 |
|
[Post-surgical lymphocutaneous fistula, chylous ascites and chylothorax--infrequent but serious complications: etiology, diagnosis and therapeutic options]. | 2007 Dec |
|
Dissociation between cortical activation and cognitive performance under pharmacological blood pressure elevation in chronic hypotension. | 2007 Jul |
|
[A complicated course after esophagogastrectomy]. | 2007 May-Jun |
|
Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of phenylephrine in human plasma and its application to a pharmacokinetic study. | 2007 Oct 15 |
|
Chylous ascites following radical nephrectomy: a case report. | 2008 Jan 11 |
|
Effect of systemic blood pressure on microcollateral circulation evaluated by real-time contrast echocardiography. | 2008 Jun |
|
alpha-Adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data. | 2009 Jul |
|
Etilefrinhydrochloride tablet ingestion: successful therapy by endoscopic removal of tablet conglomerate. | 2009 Mar-Apr |
|
Epidemiological analysis of doping offences in the professional tennis circuit. | 2010 Dec 15 |
|
Comparison of two protective lung ventilatory regimes on oxygenation during one-lung ventilation: a randomized controlled trial. | 2010 Nov 2 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10758467
15 mg (30 drops)
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:55:15 UTC 2022
by
admin
on
Fri Dec 16 19:55:15 UTC 2022
|
Record UNII |
ZB6F8MY53V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01CA51
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
||
|
WHO-VATC |
QC01CA01
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/02/122
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
||
|
NCI_THESAURUS |
C29747
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
||
|
WHO-ATC |
C01CA01
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
||
|
WHO-ATC |
C01CA51
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1101
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
2229
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
CHEMBL86882
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
C65576
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
10128-36-6
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
SUPERSEDED | |||
|
DB08985
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
SUB07303MIG
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
M5184
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | Merck Index | ||
|
2409-85-0
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
SUPERSEDED | |||
|
4169
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | RxNorm | ||
|
Etilefrine
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
D005039
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
ZB6F8MY53V
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
DTXSID1023029
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
233-359-9
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
ALTERNATIVE | |||
|
211-910-4
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
709-55-7
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY | |||
|
3306
Created by
admin on Fri Dec 16 19:55:16 UTC 2022 , Edited by admin on Fri Dec 16 19:55:16 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE | |||
|
TARGET -> AGONIST | |||
|
TRANSPORTER -> INHIBITOR | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |